ARS Pharmaceuticals, Inc. (SPRY)
| Market Cap | 360.90M -59.2% |
| Revenue (ttm) | 122.14M -14.5% |
| Net Income | -199.87M |
| EPS | -2.01 |
| Shares Out | 100.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,284,903 |
| Open | 3.850 |
| Previous Close | 3.890 |
| Day's Range | 3.590 - 4.000 |
| 52-Week Range | 2.440 - 13.150 |
| Beta | 1.16 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+373.54%) |
| Earnings Date | Nov 5, 2026 |
About SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SPRY stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 373.54% from the latest price.
News
ARS Pharmaceuticals price target lowered to $20 from $30 at Cantor Fitzgerald
Cantor Fitzgerald analyst Josh Schimmer lowered the firm’s price target on ARS Pharmaceuticals (SPRY) to $20 from $30 and keeps an Overweight rating on the shares. Despite Neffy sales falling…
ARS Pharmaceuticals downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Ryan Deschner downgraded ARS Pharmaceuticals (SPRY) to Outperform from Strong Buy with a price target of $17, down from $28. ARS Pharmaceuticals’ weaker-than-expected peak-quarte...
ARS Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 neffy demand rose 42% YoY and U.S. market share exceeded 5%, while SG&A fell more than 40% from the H1 quarterly average. The year-end 2027 cash flow breakeven target was reaffirmed, with ARS-2 interim data expected in Q1 2027.
ARS Pharmaceuticals Earnings release: Q3 2026
ARS Pharmaceuticals released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
ARS Pharmaceuticals Quarterly report: Q3 2026
ARS Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 5, 2026.
ARS Pharmaceuticals reports Q3 EPS (36c), consensus (33c)
Reports Q3 revenue $37.71M, consensus $41.99M. “In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow…
ARS Pharma to Report Third Quarter 2026 Financial Results
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better pr...
Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. (“ARS” or the “Company”) (NASDAQ: SPRY) o...
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) to Act Ahead of the Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (...
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (...
Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (...
ARS Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
neffy continues to gain market share in a large, underserved allergy market, with a strategic focus on provider engagement and operational efficiency. The CSU program is advancing, leveraging existing infrastructure, with key interim data expected in Q1 next year. Cash position remains strong at $144 million.
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (N...
ARS Pharmaceuticals price target lowered to $15 from $18 at Leerink
Leerink lowered the firm’s price target on ARS Pharmaceuticals (SPRY) to $15 from $18 and keeps an Outperform rating on the shares.
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent s...
Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NAS...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Wall Street called the missed CVS Caremark formulary date a "negative shock" — a securities class action alleges ARS Pharmaceuticals built analyst expectations on a July 1, 2026 coverage timeline that...
SPRY Investors Have Rights – If You Lost Money Investing in ARS Pharmaceuticals Inc. Contact Robbins LLP for Information Recovering Your Losses
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceu...
Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026
New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NAS...
ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c)
Reports Q2 revenue $33.66M, consensus $31.32M. “It is a privilege to lead ARS Pharma at this pivotal time, and my conviction in the opportunity ahead has only grown since stepping…
ARS Pharmaceuticals sees cash flow break-even by end of 2027
The company said in its earnings release, “Based on its revised cash-based expense plan, ARS Pharma anticipates a path to reaching cash flow breakeven by the end of 2027.” ARS…
ARS Pharmaceuticals names Meg Smith as Chief Commercial Officer
ARS Pharmaceuticals (SPRY) announced the appointment of Meg Smith as Chief Commercial Officer, effective August 17. Smith most recently led the commercial organization at Dynavax Technologies. “neffy ...
Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026
New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NAS...
ARS Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 revenue reached $33.7M with neffy U.S. market share doubling year-over-year to 5%. Strategic focus shifted to provider engagement, cost discipline, and pipeline expansion, with cash flow breakeven targeted by end of 2027.
ARS Pharmaceuticals Earnings release: Q2 2026
ARS Pharmaceuticals released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.